These findings indicate that targeting ENO1 with PhAH constrains the influence of osteoblasts on PCa cells and increases the sensitivity of tumors to chemotherapy, thereby serving as an effective therapeutic strategy for bmCRPC. Here, ENO1 is linked to posterior cortical atrophy.